Availability, Standardization and Safety of Human Cells and Tissues for Drug Screening and Testing

Stacey, Glyn; Thomas, Hartung

doi:10.1002/9783527609611.ch9

Cited by 7 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A broad range of issues in securing tissues for testing were addressed at the 32 nd Workshop of the European Centre for Validation of Alternative Methods (Anderson et al, 1998 [7] ). Where tissues cannot be sourced via a qualified tissue bank, there should be an agreed testing method in place with clinical contacts regarding all aspects of harvesting, preparation, labelling, storage and transfer; for an example see (Stacey and Hartung, 2006 [8] ). It is also important to assess the risks of viral contamination of primary cells and tissues.…”

Section: Cell and Tissue Sourcingmentioning

confidence: 99%

“…It is also important to assess the risks of viral contamination of primary cells and tissues. More details on approaches for risk assessment of primary cells and tissues are described in (Stacey and Hartung, 2006 [8] ). Tissues should be obtained from tissue banks holding only materials from screened donors and this will significantly assist in managing viral safety issues.…”

Section: Cell and Tissue Sourcingmentioning

confidence: 99%

See 1 more Smart Citation

Biokinetics and xenobiotic bioavailability

2018

OECD Series on Testing and Assessment

View full text Add to dashboard Cite

Section: Cell and Tissue Sourcingmentioning

confidence: 99%

Section: Cell and Tissue Sourcingmentioning

confidence: 99%

Biokinetics and xenobiotic bioavailability

2018

OECD Series on Testing and Assessment

View full text Add to dashboard Cite

“…This problem has been addressed earlier in the context of developing a Good Cell Culture Practice. 5,70 It remains a grave concern, and has been put forward more recently. [71][72][73][74] There is compelling evidence that 15-20% of the cells used in experiments are not what they are supposed to be.…”

Section: Anaerobic Cells Cannot Be Expected To Show Normal Physiological Reactionsmentioning

confidence: 99%

Alternative in vitro assays in nanomaterial toxicology

Hartung

Sabbioni

2011

WIREs Nanomed Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

Nanomaterials are acclaimed for their novel properties, for which broad new uses are being discovered with increasing frequency. It is obvious that, as the properties change, unwanted properties (toxicity) are to be expected as well. Current toxicology, however, is already overwhelmed with the challenge of addressing new chemicals, not to mention the enormous number of old chemicals never properly assessed. Limitations of traditional approaches range from animal welfare issues, which were a strong driving force for alternative approaches (the 3Rs concept) over the last two decades, to aspects of throughput and accuracy of the predicted toxicities. The latter has prompted discussion about a revolutionary change in chemical safety assessment, now known as Toxicology for the 21st Century (Tox-21c). The multitude of possible formulations of nanomaterials to be assessed for novel toxic properties makes these alternative approaches especially attractive, given the well recognized limitations of traditional animal-based approaches--limitations that might be even more pronounced for nanomaterials, which have notably altered biokinetics.

show abstract

“…This problem has been addressed earlier by us in the context of developing a Good Cell Culture Practice (Hartung et al, 2002;Coecke et al, 2005;Stacey and Hartung, 2007). However, it remains a grave concern and, following Aldous Huxley in his famous book, Brave New World, "Sixty-two thousand four hundred repetitions make one truth".…”

Section: Problem 6: Cell Authenticity and Crosscontamination -Cells Imentioning

confidence: 99%